RaySearch Laboratories

RaySearch publishes Annual Report for 2023

Retrieved on: 
금요일, 4월 26, 2024

STOCKHOLM, April 26, 2024 /PRNewswire/ -- Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023.

Key Points: 
  • STOCKHOLM, April 26, 2024 /PRNewswire/ -- Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023.
  • The report is held available on RaySearch's website, under the section Investors.
  • This information is information that RaySearch Larboratiories AB (publ) is obliged to make public pursuant to the Securities Markets Act.
  • The information was submitted for publication at 08:30 am CEST, on April 26, 2024.

Raigmore Hospital in Scotland selects RayCare

Retrieved on: 
수요일, 4월 17, 2024

STOCKHOLM, April 17, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®*.

Key Points: 
  • STOCKHOLM, April 17, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®*.
  • The radiotherapy center at Raigmore Hospital is the northernmost center for radiotherapy in the UK, treating close to 1,000 patients per year.
  • Steven Colligan, Head of radiotherapy physics, Raigmore Hospital, says: "We have used RayStation since 2016 and look forward to the introduction of RayCare to the department.
  • Johan Löf, founder and CEO, RaySearch, says: "Our installed base of RayCare customers is steadily increasing and I am happy to welcome Raigmore Hospital as a new RayCare customer.

World leading carbon ion center QST in Japan selects RayStation

Retrieved on: 
목요일, 4월 11, 2024

STOCKHOLM, April 11, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that QST, National Institutes for Quantum Science and Technology in Chiba, Japan, has selected the treatment planning system RayStation®* for clinical use at the QST hospital.

Key Points: 
  • STOCKHOLM, April 11, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that QST, National Institutes for Quantum Science and Technology in Chiba, Japan, has selected the treatment planning system RayStation®* for clinical use at the QST hospital.
  • This was followed by a research collaboration agreement in 2022, with focus on advancing ion beam therapy via the pencil beam scanning technique.
  • Ion beam therapy is a highly advanced form of radiation therapy in which tumors are treated with protons or heavier ions such as helium or carbon.
  • NIRS pioneered the clinical application of ion beam therapy during the 1990s and today, QST is a leading center for carbon ion therapy with more than 15,000 patients who have been treated at the HIMAC facility in Chiba.

RaySearch to present latest innovations in RayStation, RayCare and RayIntelligence at ISOP and NPC (NAPT)

Retrieved on: 
목요일, 4월 4, 2024

STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.

Key Points: 
  • STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.
  • Visit us at RaySearch's table at ISOP and booth at NPC.
  • The focus during both ISOP and NPC will be on support for proton arcs and robust optimization based on linear energy transfer (LET) and adaptive therapy.
  • Marc Mlyn, President of RaySearch Americas, and David McPhail, VP of Sales for RaySearch Americas, will be present at the meetings and look forward to meeting existing and future clinical partners.

RaySearch Laboratories: Year-end report 2023

Retrieved on: 
금요일, 2월 23, 2024

RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.

Key Points: 
  • RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.
  • The Royal Marsden in the UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
  • Telephone: +46 (0)8 510 530 00, [email protected]
    Telephone: +46 (0)8 510 530 00, [email protected]
    The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act.
  • CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's year-end report for January-December 2023 at a webcast to be held in English on Friday, February 23, 2024 at 10:00-10:30 a.m. CET.

The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch

Retrieved on: 
목요일, 2월 8, 2024

Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.

Key Points: 
  • Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.
  • ARTemis is a collaborative effort between RaySearch and Accuray, aiming to provide an online adaptive solution for clinicians using the RayStation treatment planning system with the Radixact Treatment Delivery System.
  • The Royal Marsden in Sutton plans to implement the full ARTemis package, which has also been funded by The Royal Marsden Cancer Charity.
  • Johan Löf, founder and CEO, RaySearch, says: "I am a strong believer of the clinical benefits of adaptive radiation therapy.

RayStation in more than 1,000 radiotherapy centers worldwide

Retrieved on: 
수요일, 1월 31, 2024

STOCKHOLM, Jan. 31, 2024 /PRNewswire/ -- RaySearch Laboratories AB (pub) is proud to announce that the number of radiotherapy centers that have chosen RayStation®* for treatment planning now exceeds 1,000.

Key Points: 
  • STOCKHOLM, Jan. 31, 2024 /PRNewswire/ -- RaySearch Laboratories AB (pub) is proud to announce that the number of radiotherapy centers that have chosen RayStation®* for treatment planning now exceeds 1,000.
  • The first version of RayStation was launched in 2009 and the system is now available in cancer centers in 43 countries worldwide.
  • The United States has the largest number of RayStation centers with more than 285 customers, followed by Japan, with around 220 centers, and China, where around 90 centers have bought RayStation.
  • The first ever customer for RayStation was Westdeutsches Protonentherapiezentrum Essen (WPE) in Germany, who bought RayStation in 2009.

The Froedtert & Medical College of Wisconsin health network selects RayStation

Retrieved on: 
목요일, 1월 18, 2024

STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.

Key Points: 
  • STOCKHOLM, Jan. 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*.
  • The Froedtert & MCW health network has purchased RayStation for photon treatments on its Elekta linear accellerators and the Accuray Radixact® treatment delivery system, as well as hyperscanning proton licenses for the health network's upcoming Mevion S250i proton therapy system.
  • The Froedtert & MCW health network offers a nationally and internationally recognized premier cancer program with six cancer centers anchored by the only academic medical center in eastern Wisconsin.
  • The Clinical Cancer Center at the health network's Froedtert Hospital campus anticipates being the first center in Wisconsin to offer proton therapy.

RaySearch releases RayStation 2024A

Retrieved on: 
금요일, 12월 22, 2023

STOCKHOLM, Dec. 22, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2024A, the latest version of the company's comprehensive treatment planning system.

Key Points: 
  • STOCKHOLM, Dec. 22, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2024A, the latest version of the company's comprehensive treatment planning system.
  • RayStation 2024A also brings the possibility to define clinical planning goals for both the combined plan and the constituent sub-plans, and evaluate correspondingly.
  • The workflow for enhancing daily images to allow for accurate dose computation is further improved with RayStation 2024A.
  • With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years."

Vejle Hospital becomes first center in the world to use RayStation for an online adaptive treatment with augmented CBCT

Retrieved on: 
월요일, 11월 20, 2023

The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.

Key Points: 
  • The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient.
  • Thanks to the synthetic CT algorithm and fast adaptive replanning capabilities in RayStation, the CBCT of the first treatment fraction can be used for creating an adapted plan during the treatment session.
  • In the current example, the online adaptation was motivated by differences in positioning at image acquisition and at treatment.
  • RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments."